| abstract |
In one aspect, the invention provides an androgen receptor targeting agent (ARTA). The agent defines a new subclass of compounds that are selective androgen receptor modulators (SARMs). Several SARM compounds have been shown to exhibit androgen and anabolic activity of nonsteroidal ligands against unexpected androgen receptors. Other SARM compounds have been shown to have antiandrogen activity of nonsteroidal ligands against androgen receptors that are unexpected. The SARM compound, alone or as a composition, may comprise a) male contraception; b) various hormone-related symptoms such as tiredness, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, benign prostatic hyperplasia, emotional and cognitive changes, And treatment of symptoms associated with androgen lowering (ADAM) in older men, such as prostate cancer; c) in women, such as sexual dysfunction, decreased libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, cognitive and emotional changes, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer, and ovarian cancer Treatment of symptoms associated with androgen lowering (ADIF); d) treating and / or preventing acute and / or chronic muscle wasting; e) prevention and / or treatment of dry eye syndrome; f) oral androgen replacement therapy; And / or g) reduce the incidence, arrest or regression of prostate cancer. |